West Pharmaceutical Services, Inc. with ticker code (WST) now have 7 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $470.00 and $355.00 suggesting an average Analsyt target price of $400.43. Given that the stocks previous close was at $367.44 this now indicates there is a potential upside of 9.0%. Also worth taking note is the 50 day moving average now sits at $362.98 while the 200 day moving average is $366.64. The market capitalization for the company is 26.63B. The stock price is currently at: $363.29 USD
The potential market cap would be $29,019,733,216 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 46.1, revenue per share of $39.70 and a 11.93% return on assets.
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
